Discovery of novel and potent CDK8 inhibitors for the treatment of acute myeloid leukaemia

References

• Yogarajah M, Stone RM. A concise review of BCL-2 inhibition in acute myeloid leukemia. Expert Rev Hematol. 2018;11(2):145–154.
   PubMed Web of Science ®Google Scholar
• Cao Z, Shu Y, Wang J, Wang C, Feng T, Yang L, Shao J, Zou L. Super enhancers: Pathogenic roles and potential therapeutic targets for acute myeloid leukemia (AML). Genes Dis. 2022;9(6):1466–1477.
   PubMed Web of Science ®Google Scholar
• Kayser S, Levis MJ. Updates on targeted therapies for acute myeloid leukaemia. Br J Haematol. 2022;196(2):316–328.
   PubMed Web of Science ®Google Scholar
• Thol F, Ganser A. Treatment of relapsed acute myeloid leukemia. Curr Treat Options Oncol. 2020;21(8):66.
   PubMed Web of Science ®Google Scholar
• Hosono N, Yokoyama H, Aotsuka N, Ando K, Iida H, Ishikawa T, Usuki K, Onozawa M, Kizaki M, Kubo K, et al. Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia. Int J Clin Oncol. 2021;26(11):2131–2141.
   PubMed Web of Science ®Google Scholar
• Brachet-Botineau M, Deynoux M, Vallet N, Polomski M, Juen L, Hérault O, Mazurier F, Viaud-Massuard MC, Prié G, Gouilleux F. A novel inhibitor of STAT5 signaling overcomes chemotherapy resistance in myeloid leukemia cells. Cancers. 2019;11(12):2043.
   PubMed Web of Science ®Google Scholar
• Rzymski T, Mikula M, Żyłkiewicz E, Dreas A, Wiklik K, Gołas A, Wójcik K, Masiejczyk M, Wróbel A, Dolata I, et al. SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains. Oncotarget. 2017;8(20):33779–33795.
   PubMedGoogle Scholar
• Wingelhofer B, Maurer B, Heyes EC, Cumaraswamy AA, Berger-Becvar A, de Araujo ED, Orlova A, Freund P, Ruge F, Park J, et al. Pharmacologic inhibition of STAT5 in acute myeloid leukemia. Leukemia. 2018;32(5):1135–1146.
   PubMed Web of Science ®Google Scholar
• Yoshimoto G, Miyamoto T, Jabbarzadeh-Tabrizi S, Iino T, Rocnik JL, Kikushige Y, Mori Y, Shima T, Iwasaki H, Takenaka K, et al. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood. 2009;114(24):5034–5043.
   PubMed Web of Science ®Google Scholar
• Cee VJ, Chen DY, Lee MR, Nicolaou KC. Cortistatin A is a high-affinity ligand of protein kinases ROCK, CDK8, and CDK11. Angew Chem Int Ed Engl. 2009;48(47):8952–8957.
   PubMed Web of Science ®Google Scholar
• Yu M, Long Y, Yang Y, Li M, Teo T, Noll B, Philip S, Wang S. Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation. Eur J Med Chem. 2021;218:113391.
   PubMed Web of Science ®Google Scholar
• Lee JC, Liu S, Wang Y, Liang Y, Jablons DM. MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway. Oncotarget. 2022;13(1):1217–1236.
   PubMedGoogle Scholar
• Dale T, Clarke PA, Esdar C, Waalboer D, Adeniji-Popoola O, Ortiz-Ruiz MJ, Mallinger A, Samant RS, Czodrowski P, Musil D, et al. A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease. Nat Chem Biol. 2015;11(12):973–980.
   PubMed Web of Science ®Google Scholar
• Mallinger A, Schiemann K, Rink C, Stieber F, Calderini M, Crumpler S, Stubbs M, Adeniji-Popoola O, Poeschke O, Busch M, et al. Discovery of potent, selective, and orally bioavailable small-molecule modulators of the mediator complex-associated kinases CDK8 and CDK19. J Med Chem. 2016;59(3):1078–1101.
   PubMed Web of Science ®Google Scholar
• Czodrowski P, Mallinger A, Wienke D, Esdar C, Pöschke O, Busch M, Rohdich F, Eccles SA, Ortiz-Ruiz MJ, Schneider R, et al. Structure-based optimization of potent, selective, and orally bioavailable CDK8 inhibitors discovered by high-throughput screening. J Med Chem. 2016;59(20):9337–9349.
   PubMed Web of Science ®Google Scholar
• Hofmann MH, Mani R, Engelhardt H, Impagnatiello MA, Carotta S, Kerenyi M, Lorenzo-Herrero S, Böttcher J, Scharn D, Arnhof H, et al. Selective and potent CDK8/19 inhibitors enhance NK-cell activity and promote tumor surveillance. Mol Cancer Ther. 2020;19(4):1018–1030.
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim GmbH. New phenyl pyrazolyl acetamide compounds and derivatives as CDK8/CDK19 inhibitors [P]. WO2017202719A1, 2017.11.30.
   Google Scholar
• NIH. U.S. National Library of Medicine. https://clinicaltrials.gov. (accessed May 25, 2023).
   Google Scholar
• Yu M, Teo T, Yang Y, Li M, Long Y, Philip S, Noll B, Heinemann GK, Diab S, Eldi P, et al. Potent and orally bioavailable CDK8 inhibitors: design, synthesis, structure-activity relationship analysis and biological evaluation. Eur J Med Chem. 2021;214:113248.
   PubMed Web of Science ®Google Scholar
• Solum E, Hansen TV, Aesoy R, Herfindal L. New CDK8 inhibitors as potential anti-leukemic agents - design, synthesis and biological evaluation. Bioorg Med Chem. 2020;28(10):115461.
   PubMed Web of Science ®Google Scholar
• Zhang XX, Yan YY, Ma X, Xiao Y, Lei CC, Wang YM, Liu C, Wang Q, Zhang XT, Cheng WD, et al. Discovery of a novel oral type I CDK8 inhibitor against acute myeloid leukemia. Eur J Med Chem. 2023;251:115214.
   PubMed Web of Science ®Google Scholar
• Xie Z, Hou S, Yang X, Duan Y, Han J, Wang Q, Liao C. Lessons learned from past cyclin-dependent kinase drug discovery efforts. J Med Chem. 2022;65(9):6356–6389.
   PubMed Web of Science ®Google Scholar
• Yan YY, Zhang XX, Xiao Y, Shen XB, Jian YJ, Wang YM, She ZH, Liu MM, Liu XH. Design and synthesis of a 2-amino-pyridine derivative as a potent CDK8 inhibitor for anti-colorectal cancer therapy. J Med Chem. 2022;65(19):13216–13239.
   PubMed Web of Science ®Google Scholar
• Bancerek J, Poss ZC, Steinparzer I, Sedlyarov V, Pfaffenwimmer T, Mikulic I, Dölken L, Strobl B, Müller M, Taatjes DJ, et al. CDK8 kinase phosphorylates transcription factor STAT1 to selectively regulate the interferon response. Immunity. 2013;38(2):250–262.
   PubMed Web of Science ®Google Scholar